Genetically Proxied Therapeutic Effect of Metformin Use, Blood Pressure, and Hypertension’s Risk: a Drug Target-Based Mendelian Randomization Study

J Cardiovasc Transl Res. 2023 Nov 27. doi: 10.1007/s12265-023-10460-z. Online ahead of print.


In this work, we aim to evaluate the association of the genetically proxied effect of metformin on blood pressure (BP) and hypertension through a drug target-based Mendelian randomization (MR) analysis. Thirty-two instrumental variables for five metformin targets (i.e., AMP-activated protein kinase (AMPK), growth differentiation factor 15 (GDF15), mitochondrial glycerol 3 (MG3), mitochondrial complex I (MCI), and glucagon (GCG)) were introduced to the MR analysis on the datasets of hypertension, systolic and diastolic blood pressure (SBP and DBP). The MR analyses demonstrated that the MCI- and MG3-specific metformin’s use would significantly reduce SBP, DBP, and hypertension risk. The meta-analyses showed that the genetically proxied metformin’s use equivalent to a 6.75 mmol/mol reduction on HbA1c could decrease both the SBP (beta = – 1.05, P < 0.001) and DBP (beta = – 0.51, P = 0.096). Furthermore, metformin’s use was also implied to reduce the hypertension risk. The MG3- and MCI-dependent metformin’s effect may play key roles in the anti-hypertension function.

PMID:38012470 | DOI:10.1007/s12265-023-10460-z